AR056824A1 - Tableta de neramexano con matriz de liberacion modificada - Google Patents

Tableta de neramexano con matriz de liberacion modificada

Info

Publication number
AR056824A1
AR056824A1 ARP060105301A ARP060105301A AR056824A1 AR 056824 A1 AR056824 A1 AR 056824A1 AR P060105301 A ARP060105301 A AR P060105301A AR P060105301 A ARP060105301 A AR P060105301A AR 056824 A1 AR056824 A1 AR 056824A1
Authority
AR
Argentina
Prior art keywords
dosage forms
matrix
neramexane
dementia
alzheimer
Prior art date
Application number
ARP060105301A
Other languages
English (en)
Inventor
Bernhard Hauptmeier
Andreas Becker
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR056824A1 publication Critical patent/AR056824A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formas de dosificacion orales de liberacion modificada de neramexano que son de utilidad para la terapia continua de pacientes que sufren de enfermedades y afecciones tales como demencia de Alzheimer y dolor neuropático. Las composiciones tienen un perfil de liberacion de drogas que es adecuado para lograr concentraciones plasmáticas de neramexano en estado estable que presentan fluctuaciones relativamente pequenas cuando se administran con un régimen de dos veces por día o aun una vez por día. Las formas de dosificacion se pueden disenar como tabletas con matriz de liberacion modificada, que opcionalmente se recubren ara enmascarar el sabor. La presente provee además métodos terapéuticos para tratar afecciones tales como demencia de Alzheimer y dolor neuropático que comprenden la administracion de dichas formas de dosificacion.
ARP060105301A 2005-11-30 2006-11-30 Tableta de neramexano con matriz de liberacion modificada AR056824A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74097505P 2005-11-30 2005-11-30

Publications (1)

Publication Number Publication Date
AR056824A1 true AR056824A1 (es) 2007-10-24

Family

ID=37698309

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105301A AR056824A1 (es) 2005-11-30 2006-11-30 Tableta de neramexano con matriz de liberacion modificada

Country Status (15)

Country Link
US (1) US20070141148A1 (es)
EP (1) EP1959941A1 (es)
JP (2) JP5276989B2 (es)
KR (1) KR101084832B1 (es)
CN (1) CN101300001B (es)
AR (1) AR056824A1 (es)
AU (1) AU2006319411B8 (es)
BR (1) BRPI0619384A2 (es)
CA (1) CA2624589C (es)
HK (1) HK1124762A1 (es)
IL (1) IL191578A0 (es)
RU (1) RU2422135C2 (es)
TW (1) TW200738228A (es)
WO (1) WO2007062815A1 (es)
ZA (1) ZA200803172B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200916091A (en) * 2007-06-08 2009-04-16 Merz Pharma Gmbh & Amp Co Kgaa Neramexane for the treatment of nystagmus
JP5613053B2 (ja) * 2007-09-12 2014-10-22 メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン 耳鳴を処置するための間欠療法
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
WO2010028769A1 (en) * 2008-09-10 2010-03-18 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
BRPI0923377A2 (pt) * 2008-12-19 2015-07-21 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos
RU2513090C2 (ru) 2009-04-17 2014-04-20 Мерц Фарма Гмбх Унд Ко. Кгаа Синтез мезилата 1-амино-1,3,3,5,5-пентаметилциклогексана
WO2011000541A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co Kgaa Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
WO2011000538A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing neramexane
BRPI1012674A2 (pt) * 2009-06-29 2016-04-05 Merz Pharma Gmbh & Co Kgaa metodo de preparacao de 1-amino-1,3,3,5,5-pentametilciclohexano ou um sal farmaceuticamente aceitavel do mesmo, 1-amino-1,3,3,5,5-pentametilciclohexano ou um sal farmaceuticamente aceitavel do mesmo
EP2467131A4 (en) * 2009-08-21 2014-02-19 Univ Florida FORMULATIONS OF ANABASEIN COMPOUNDS WITH TAXED RELEASE AND THEIR USE
EP2477606A1 (de) * 2009-09-18 2012-07-25 Basf Se Schnell lösliche feste pharmazeutische zubereitungen enthaltend amphiphile copolymere auf basis von polyethern in kombination mit hydrophilen polymeren
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
AU2011267348A1 (en) 2010-06-18 2012-10-25 Merz Pharma Gmbh & Co. Kgaa Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives
WO2011160839A1 (en) 2010-06-24 2011-12-29 Merz Pharma Gmbh & Co. Kgaa Neramexane multiple unit dosage form
AU2011302006A1 (en) * 2010-09-15 2013-03-07 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012098000A1 (en) 2011-01-20 2012-07-26 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
ES2644698T3 (es) * 2013-06-12 2017-11-30 Novartis Ag Formulación de liberación modificada

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3007387B2 (ja) * 1990-07-16 2000-02-07 エーザイ株式会社 徐放性製剤用基剤粉末
DE4443358A1 (de) * 1994-12-06 1996-06-13 Basf Ag Depot-Arzneimittel
DK1009732T3 (da) * 1997-06-30 2003-09-22 Merz Pharma Gmbh & Co Kgaa 1-Amino-alkylcyclohexan NMDA receptor antagonister
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
CA2504038A1 (en) * 2002-10-31 2004-05-21 Alza Corporation Dosage form providing ascending release of liquid formulation
US7704528B2 (en) * 2003-05-05 2010-04-27 Isp Investments Inc. Binder composition and method for processing poorly compressible drugs into tablets of predetermined hardness and friability
MXPA05012493A (es) * 2003-05-27 2006-05-25 Forest Laboratories Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
EP1660058A2 (en) * 2003-07-28 2006-05-31 Merz Pharma GmbH & Co. KGaA The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
US20050123502A1 (en) * 2003-10-07 2005-06-09 Chan Shing Y. Nicotine containing oral compositions
ATE411015T1 (de) * 2003-10-22 2008-10-15 Merz Pharma Gmbh & Co Kgaa Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
BRPI0508743A (pt) * 2004-03-24 2008-01-22 Lupin Ltd composição farmacêutica com uma liberação estendida de eritromicina ou um derivado da mesma, método para o uso de uma composição farmacêutica e processo para a preparação de uma composição farmacêutica
EA011446B1 (ru) * 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
SG157415A1 (en) * 2004-11-23 2009-12-29 Adamas Pharmaceuticals Inc Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
EP2623099A1 (en) * 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EP1898890A1 (en) * 2005-06-16 2008-03-19 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation

Also Published As

Publication number Publication date
CA2624589A1 (en) 2007-06-07
KR101084832B1 (ko) 2011-11-21
ZA200803172B (en) 2009-03-25
CA2624589C (en) 2011-05-24
AU2006319411A1 (en) 2007-06-07
JP5276989B2 (ja) 2013-08-28
WO2007062815A1 (en) 2007-06-07
CN101300001B (zh) 2011-12-14
JP5745556B2 (ja) 2015-07-08
CN101300001A (zh) 2008-11-05
AU2006319411B8 (en) 2010-10-21
IL191578A0 (en) 2008-12-29
JP2013136620A (ja) 2013-07-11
KR20080069218A (ko) 2008-07-25
RU2008126212A (ru) 2010-01-10
TW200738228A (en) 2007-10-16
JP2009517420A (ja) 2009-04-30
BRPI0619384A2 (pt) 2011-10-04
EP1959941A1 (en) 2008-08-27
RU2422135C2 (ru) 2011-06-27
AU2006319411B2 (en) 2010-09-16
HK1124762A1 (en) 2009-07-24
US20070141148A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
Yang et al. Mechanistic target of rapamycin–independent antidepressant effects of (R)-ketamine in a social defeat stress model
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
BRPI0707235B1 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
ECSP15039103A (es) Formulación de liberación sostenida de mosapride que proporciona efectos farmacológicos y clínicos con administración una vez al día
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
BRPI0517391A (pt) forma de dosagem com lapso de tempo de medicamentos para a terapia de insÈnia
EP1849462A3 (en) A method of alleviating signs and symptons of Spasticity
JP2018507243A5 (es)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
RS20080497A (en) Novel low dose pharmaceutical compositions comrising nimesulide, preparation and use thereof
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
BR112013000190A2 (pt) formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
JP2013541583A5 (es)
ECSP099348A (es) Composición farmacéutica de liberación modificada de un músculo relajante y un aine
RU2020107732A (ru) Схема дозирования модулятора s1p с немедленным высвобождением
RU2012157328A (ru) Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера
NO20080244L (no) Doseringsstyring for prasugrel
JP2014507475A5 (es)
AR073796A1 (es) Formulaciones de corticosteroides y sus metodos de tratamiento
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
JP2016505050A5 (es)
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal